The present application relates to the field of biological
medicine, and specifically provides an anti-LILRB4
monoclonal antibody injection preparation, which comprises an anti-LILRB4
monoclonal antibody, a buffer salt, a
protein protective agent, and a surfactant, wherein the pH of the injection preparation is 5.5-6.5. The injection preparation provided by the present application provides a good storage environment for the anti-LILRB4
monoclonal antibody through the synergistic interaction of different contents of the buffer salt, the
protein protective agent, and the surfactant, and guarantees the
biological activity of the anti-LILRB4
monoclonal antibody. The anti-LILRB4
monoclonal antibody can effectively inhibit the combination of the LILRB4
antigen and its ligand complex, thereby blocking the interaction with the ligand ApoE complex, preventing the activation of the downstream NF-kappa B
signal pathway and the release of ARG1, preventing the inhibition of
T cell proliferation and the promotion of tissue infiltration, and can be used for treating
cancer.